arrow
E

Emiliano Tamburini

cardinale panico tricase city hospital
H指数:35
被引数:4,682

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma

中心级方案依从性对胰腺导管腺癌新辅助治疗结局的影响

2026-09-010
PRE
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting

根据TOPAZ-1研究入组标准评估顺铂、吉西他滨和度伐利尤单抗的疗效:一项真实世界环境下的全球性大规模分析

2026-08-160
PRE
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Prognostic impact of variants of uncertain significance (VUS) in BRCA genes and homologous recombination repair (HRR) genes in prostate cancer: a real-world multicenter study

BRCA基因和同源重组修复(HRR)基因中意义不明的变异(VUS)对前列腺癌预后的影响:一项真实世界多中心研究

2026-08-040
OA
Role and Characteristic of Multidisciplinarity in Hepatocellular Carcinoma Management and Care Pathway Certification: Bottom-Up Approach of the MDT Project in Italy

多学科性在肝细胞癌管理及护理路径认证中的角色与特征:意大利MDT项目的自下而上方法

2026-05-200
OAAI
Early and Late Survival Dynamics of Immunotherapy Combinations in Advanced HCC: Anchored Indirect Comparison of Atezolizumab plus Bevacizumab versus Durvalumab + Tremelimumab

晚期肝细胞癌免疫疗法联合方案的早期与晚期生存动态:阿替利珠单抗联合贝伐珠单抗与度伐利尤单抗联合特瑞普利单抗的锚定间接比较

2026-04-210
PRE
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab

接受顺铂、吉西他滨和度鲁特韦治疗的胆道癌患者中,转移部位对预后的影响

2026-02-270
PRE
HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI

HER-2基因改变作为接受FOLFIRI治疗的转移性结直肠癌患者的生物标志物

2026-01-010
OA
Estimating the clinical benefit of metastases resection in liver-limited metastatic colorectal cancer: an IPD-based pooled analysis of nine randomized trials

评估肝转移性结直肠癌中转移灶切除的临床获益:一项基于IPD的九项随机试验的合并分析

2026-01-010
OAAI
CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer

CombiCoR-Vax试验:一项关于序贯使用帕博利珠单抗联合树突状细胞疫苗,随后使用曲氟尿苷/ tipiracil 和贝伐珠单抗治疗难治性微卫星稳定型转移性结直肠癌的II期、单臂、多中心试验的研究方案

2025-11-230
OA
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial

术前mFOLFIRINOX与PAXG对比治疗I~III期可切除及临界可切除胰腺导管腺癌(PACT-21 CASSANDRA):一项随机、开放标签、2×2析因设计III期试验的首个随机化分析结果

2025-11-200
PRE
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy

微卫星稳定型结直肠癌中高肿瘤突变负荷的基因组分析揭示了抗-EGFR治疗后MAPK信号通路的改变

2025-10-280
OAAI
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study

整合组织与液体活检综合基因组分析以预测抗EGFR疗法在转移性结直肠癌中的疗效:CAPRI-2 GOIM研究的结果

2025-07-120
PRE
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population

阿特珠单抗联合贝伐珠单抗与仑伐替尼对比用于巴塞罗那临床肝癌分期B期(BCLC-B)肝细胞癌(HCC)患者:一项真实世界人群研究

2025-06-090
PRE
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies

FOLFOXIRI和FOLFOX/FOLFIRI两种一线方案,无论是否联合贝伐珠单抗,其相对剂量强度均会影响转移性结直肠癌患者的预后:TRIBE和TRIBE2研究的合并分析

2025-06-010
PRE